Daily Market Movers 12-7-07

FEATURED COMPANY

BIGSTRING CORPORATION (OTCBB: BSGC)
"Up 14.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BSGC.php

Company Profile: http://www.otcpicks.com/bigstring/bigstring.htm

BigString Corporation, through its subsidiary, BigString Interactive, Inc., provides email services. It offers BigString, which is a Web-based, POP3 server email service solution that allows the user to edit, recall, cancel, and erase the email, as well as insert or delete attachments, even after the email has been sent out and opened. The company also provides BigString Beta 2.0 that offers erasable, recallable, and self destroying applications, non-printable and non-forwardable emails, set time or number of views, and masquerading to protect the sender's privacy and security. BigString Beta 2.0 also provides spam filters, virus protection, and large-storage web-based email accounts. The company's products include BigString Free, which provides the features of BigString Beta 2.0, and includes 1GB of storage and permits the user to send unlimited emails per month; BigString Premium, which offers the features of the BigString Free account, plus vanity domains, POP3 access using any email client, 2GB of storage, and 30 minute video email; and BigString Business that offers the features of the BigString Premium account, plus 10 email accounts, 20GB of storage, global filter notification, and email management. BigString Corporation also offers BigString Marketer Pro, which provides an enterprise marketing software application which allows for the sending of interactive video email commercials that can be programmed to self-destruct at a set time; and BigString Marketer SMB, a hosted video email marketing platform for small and medium size businesses. The company was founded in 2003. It was formerly known as Recall Mail Corporation and changed its name to BigString Corporation in 2005. Bigstring Corporation is based in Red Bank, New Jersey.

BSGC News:

November 27 - iRazoo Search Portal Launches Email Powered by BigString

BigString Corporation (OTCBB: BSGC) (www.BigString.com), announced that it will be the private label email provider for the new email offering by the iRazoo search portal (www.irazoo.com).

iRazoo’s users will be able to sign-up for a free, iRazoo.com email account, offering all the functionalities of BigString's patent-pending email services, including self-destructing, tracking and video email.

Darin Myman, President and CEO of BigString Corporation noted, "iRazoo’s use of BigString is an endorsement of our ability to create white label solutions for search, social networking and video-content based companies seeking to offer their customer’s unique messaging applications that help drive and maintain traffic to their websites."

Users of the new iRazoo’s private label email will be able to send an embedded video email (up to 10 minutes in length) without the need for the recipient to click on the a link or download the video. Another unique email features allow users to remotely erase or modify emails sent to recipients, designate their emails to be non-forwardable, non-printable and/or non-savable, or opt to have their emails self-destruct after a set amount of time or views. In addition, users will also have the added security to send secure emails via an encrypted, password-protected email system that can only be open via a Secure Socket Layer (SSL).

About iRazoo

iRazoo Inc., owner and operator of iRazoo.com, is a user recommended, points driven, search engine. iRazoo's patent-pending technology refines search results from multiple search engines with user interaction for improved relevancy. In addition to highly relevant search results, users accumulate points which may be redeemed in iRazoo's reward's program.

FEATURED COMPANY

QUOTEMEDIA INC. (OTCBB: QMCI)

Detailed Quote: http://www.otcpicks.com/quotes/QMCI.php

Company Profile: http://www.otcpicks.com/quotemedia/quotemedia.htm

QuoteMedia, Inc. is a leading software developer and provider of real-time streaming financial market information, decision-support, news and research solutions to brokerage, financial services companies, business and media corporations. Among its many leading-edge products lines, the Company offers data feeds, news, dynamic market content solutions, interactive stock research tools, financial applications and real-time wireless applications. QuoteMedia provides data and services for companies such as the NASDAQ, the OTCBB, Dow Jones & Company, Forbes.com, Scotia Capital, Business Wire, Southwest Securities, Regal Securities, FBR Direct, Broadridge Financial Solutions, Inc., AIM Trimark, Zacks Investment Research, ChoiceTrade, QTrade, Schaeffer's Investment Research, Automated Financial Systems, WallStreet*E, and others. For more information, please visit: www.quotemedia.com.

QMCI News:

December 5 - QuoteMedia Brings Respected Market Data Industry Veteran Onboard; Opens NYC Office

QuoteMedia, Inc. (OTCBB: QMCI), a leading provider of market data, corporate research information and financial applications, announced today the appointment of Mr. George Katsch as Corporate Sales Director, to lead the company’s new office in New York City.

Mr. Katsch brings more than 15 years of experience in selling and supporting financial information and technology solutions to the Brokerage, Financial Service, Media Publishing and Investor Relations industries. Most recently, Mr. Katsch served as Vice President of Sales for FinancialContent, Inc., where he was responsible for business development and sales for the entire North American market. Mr. Katsch has also held key management positions with Standard and Poor’s and Interactive Data Corporation (Comstock), where he managed senior account representatives and support staff. He was principally responsible for maintaining over $50 million in revenues and generating new sales.

“George is very well-known as a successful, skilled professional in our industry, and we’re excited that he is joining the QuoteMedia sales team, heading up our New York office,” said Dave Shworan, CEO of QuoteMedia Ltd. “He brings a wealth of experience to our company, and skill sets that make him an immediately great fit with QuoteMedia, as we continue our explosive growth.”

“From within the industry, I’ve watched QuoteMedia’s remarkable growth over the past few years. I have been very impressed with QuoteMedia’s emergence as a major player in the financial data industry, and the potential for further growth is extraordinary,” said Mr. Katsch. “QuoteMedia is definitely going places, and I’m excited to be a part of it.”

FEATURED COMPANY

RENHUANG PHARMACEUTICALS (OTCBB: RHGP)

Detailed Quote: http://www.otcpicks.com/quotes/RHGP.php

Company Profile: http://www.otcpicks.com/renhuang-pharma/renhuang-pharma.htm

Renhuang Pharmaceuticals, located in Harbin of Heilongjiang Province in Northeast China, is a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, Shark Power Health Care series and Traditional Chinese Medicines. Renhuang's key product line is Acanthopanax-based products, an effective natural medicine in treating depression and melancholy and offering various other health benefits. By controlling an estimated 70% of China's natural resource of Acanthopanax (also known as Siberian Ginseng), the Company has a dominant market position in Acanthopanax-based natural medicines. The Company distributes its products through a multi-layer sales network of over 2000 sales agents. Its products are not only sold nationwide but also exported to Russia and Southeast Asia. Renhuang has established a multi-channel research and development infrastructure composed of in-house researchers, a post-doctoral working center, and collaboration with well known institutions and scientists. In manufacturing, the Company strictly follows the international GMP certified quality standards and system by utilizing cutting-edge technologies, the state of the art equipment, and the proprietary innovative and award winning processes. For more information about Renhuang Pharmaceuticals, visit www.renhuang.com.

RHGP News:

December 3 - Renhuang Pharmaceuticals Wins Olympic Year Prime Time Ad Space on CCTV

Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP) ("the Company") has bought prime time advertising slots in Central Chinese Television’s (CCTV) 2008 “Gold Ad” auction, following two of the national television network’s most heavily watched programs. The 7.5-second and 15-second air times follow CCTV’s evening news and the newsmagazine show, “Topics in Focus,”both of which are top-rated television programs in China. Both ad slots will feature Renhuang’s Ginseng and Deer Ointment product. The Company expects sales of this product to grow significantly as a result of advertising on CCTV prime time spots in the Olympic year.

“We are extremely pleased to have won the bid and look forward to promoting Renhuang products next to two of CCTV’s most popular programs,” said Jingwang Lou, general manager of sales and marketing for Renhuang Pharmaceuticals. “The exposure will build brand awareness for our products throughout China, and increase our visibility on the global basis.”

Mr. Lou said securing prime time media space was a strategic move on Renhuang’s part. “We see this as a great opportunity for Renhuang. Investing in sales and marketing is an important part of our growth strategy. We expect prime time advertising during the 2008 Beijing Olympic Games will give us international as well as domestic exposure.”

TV is the most effective media for advertisement in China. CCTV has China’s highest viewer ratings and is also broadcast internationally through sharing with other networks. In recent years, CCTV’s Gold Ad auctions for prime time advertising space have become increasingly competitive as more and more businesses select CCTV as their first media choice to promote their products. “This is the first time Renhuang has participated in the bidding process, and winning these two coveted advertising spots is a real coup,” noted Mr. Lou.

One of Renhuang’s Gold Ad spots is slated to follow the CCTV News immediately preceding the network weather forecast. “This spot has huge viewer ratings and gives us tremendous visibility and prestige,” Mr. Lou said. “This is possibly the single best time slot on Chinese TV in terms of audience reach and marketing effectiveness.”

The second gold time slot will follow the program “Topics in Focus,” an influential newsmagazine with a wide viewer following. Additionally, with special programming coverage during the 2008 Beijing Olympic Games, the “Topics in Focus” media space may provide even greater audience penetration.

FEATURED COMPANY

FRESHSTART PROPERTIES (OTC: FSPP)

Detailed Quote: http://www.otcpicks.com/quotes/FSPP.php

Company Profile: http://www.otcpicks.com/freshstart-properties/freshstart-properties.htm

Freshstart Properties, Inc. is a publicly traded real estate company focused on purchasing pre-foreclosure, foreclosure, financially distressed and bank-owed residential properties at a discount to market. The company is uniquely positioned to take advantage of the real estate, whichever direction it goes as they buy, fix and sell when prices are heading upwards and they buy, fix and hold when the market softens because they are able to command much higher rental income. The company's efforts are currently focused in and around the Pacific Northwest. For the past ten years, Freshstart's management has been buying, renovating, leasing, and selling properties in the Northwest. In that time, the company has developed a network of contacts in the Seattle-Tacoma real estate market and earned a reputation for improving neighborhoods by providing safe and affordable residences. As a publicly traded entity with access to equity markets, Freshstart enjoys a competitive advantage over similar, privately-held entities operating in the same geographical market. Freshstart Properties' primary focus is on the acquisition and preservation of older residential neighborhoods in transition where market demand is on the rise and crime rates are falling. Specifically, Freshstart Properties targets neglected and abandoned homes and multiplexes with a high probability of producing better than average capital gains once renovations are complete. The Company undertakes in-depth study of the area where properties are acquired. There are a number of factors that are taken into consideration before selecting a property for investment. This includes the cost of acquisition, prevailing property prices in that region, demographics, renovation costs, and the profitability potential of the property.

FSPP News:

November 27 - Freshstart Properties Provides a Corporate Update

Freshstart Properties, Inc. (OTC: FSPP) reports that, while the rest of the nation's real estate market is experiencing a correction from the sub-prime fallout, the Pacific Northwest market has actually made positive gains, according to the national press. This trend is expected to continue as the decline in new-housing starts, currently 7%, puts upward pressure on housing prices.

Also fueling the market's growth are the estimated 52,000 new jobs coming to the Puget Sound area over the next year.

The company is nicely positioned to take advantage of the increase in values and rents by acquiring well-selected real estate in this growing market, as witnessed by its recent acquisitions.

November 5, 2007 – The company announced that it has finalized negotiations on a purchase of an apartment building, which is located at 627 North Anderson in Tacoma, WA.

November 6, 2007 – The Company announced another property acquisition. This property is a four-unit apartment building located at 632 North Anderson in Tacoma, WA.

November 13, 2007 – The Company announced a purchase of a rental property. This property is located at 702 East 66 Street in Tacoma, WA.

The Company's website at www.freshstartpropertiesinc.com has details of its entire property portfolio.

FEATURED COMPANY

EBENEFITSDIRECT (OTC: EBFD)

Detailed Quote: http://www.otcpicks.com/quotes/EBFD.php

Company Profile:
http://www.otcpicks.com/ebenefits-direct/ebenefits-direct.htm

eBenefits Direct, Inc. is a nationwide leader in the direct marketing and distribution of a wide range of health and life insurance products to individuals, families and groups. By utilization of its many call centers across the country it enables an individual to efficiently purchase health and life insurance as well as medical and discount service programs. The company has revolutionized the way health and life insurance has historically been sold. eBenefits Direct, Inc.'s approach is through many mass distribution areas such call centers, the internet and massive lead generation programs.

EBDF News:

October 31 - eBenefits Direct, Inc. Forms Alliance With ABG

eBenefits Direct (OTC: EBFD) marketing director, Harold Halkstein, announced the company has established an alliance with ABG, a nationwide association of business owners and individuals that offers various insurance coverages to its members; its membership is available in all 50 states.

The insurance that will be offered include cancer and accident indemnity policies as well as disability income, long term care, life, dental and health insurance from major insurers. These insurers, in some cases, have for the first time agreed to offer their products nationwide through the internet and call centers for association members.

In announcing this alliance, both eBenefits Direct and ABG realize that various insurance coverages are not available directly to individuals, but rather only to employees of companies and to association members. Therefore both eBenefits Direct and ABG anticipate exceptional growth from this new relationship. Members of the ABG Association will be able to sign-up for insurance on the eBenefits Direct website, www.ebenefitsdirect.com, and they will have their own sign-in page exclusive to the members of this association.

STOCKS TO WATCH

IMAX CORPORATION (NASD: IMAX)
"Up 56.90% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/IMAX.php

IMAX Corporation, through its wholly owned subsidiaries, operates as an entertainment technology company. It specializes in digital and film-based motion picture technologies and large-format two-dimensional (2D) and three-dimensional (3D) film presentations. The company primarily engages in the design, manufacture, sale, and lease of theater systems based on patented technology for large-format, 15-perforation film frame, 70mm format theaters, including commercial theaters, museums and science centers, and destination entertainment sites. Its theater systems include projector, sound systems, and screens. IMAX Corporation also designs and manufactures high-end sound systems, as well as produces and distributes films for IMAX theaters. In addition, the company engages in the production, digital re-mastering, post-production, and distribution of 15/70-format films; the operation of IMAX theaters; and the provision of services in support of IMAX theaters and the IMAX theater network. Its institutional customers include science and natural history museums, zoos, aquaria, and other educational and cultural centers. The company also sells or leases its theater systems to theme parks, tourist destination sites, fairs, and expositions. It operates primarily in the United States, Canada, Mexico, Europe, and Asia. As of March 31, 2007, IMAX Corporation operated 284 IMAX theaters in 40 countries. The company was founded in 1967 and is headquartered in Mississauga, Canada.

IMAX News:

December 7 - IMAX signs 100-theatre deal with AMC Entertainment^TM

IMAX Corporation (NASD: IMAX) (TSX: IMX) and AMC Entertainment Inc. (AMC), one of the world's largest and most innovative theatrical exhibition companies, announced a joint-venture agreement to install 100 IMAX® digital projection systems at AMC locations in 33 major U.S. markets. The theatres will feature IMAX's digital projection system which is being developed for the IMAX MPX® theatre design. The agreement is projected to double IMAX's current commercial theatre footprint in North America and accelerates the momentum behind IMAX and AMC's transition to digital projection technology.

"We are committed to delivering a premium entertainment experience by offering a menu of entertainment alternatives inside our facilities," said Peter C. Brown, chairman and chief executive officer, AMC Entertainment Inc. "Our expanded relationship with IMAX and the deployment of its state-of-the-art, next-generation digital projection systems is a key part of our strategy of continuing to broaden and enhance the AMC experience. It also builds on the successful partnership we have had with IMAX since June of 2005 and complements our overall digital plan."

The rollout of the first 50 IMAX digital projection systems will begin in July 2008 at premier AMC theatre locations in 24 of the 33 selected markets, with an additional 25 scheduled for rollout in 2009 and 25 more in 2010. The IMAX theatres are slated to be installed in many of AMC's top-performing locations in the United States, including: AMC South Barrington 30, Chicago; AMC Mesquite 30, Dallas; AMC Gulf Pointe 30, Houston; AMC Century City 15, Los Angeles; AMC Empire 25, New York; AMC Neshaminy 24, Philadelphia; AMC Eastridge 15, San Francisco; AMC Hoffman Center 22, Washington D.C.

"The agreement cements a partnership between two great brands. Partnering with AMC in a theatre deal of this size and scope is a transformational moment for our company from both a financial and strategic perspective," said IMAX Co-Chairmen and Co-CEOs Richard L. Gelfond and Bradley J. Wechsler. "We couldn't be more pleased that The IMAX Experience® will be more accessible to consumers in nearly every major market in the United States. AMC is unique in the number of successful, stadium-seat megaplexes in locations that could accommodate this large number of new IMAX® theatres. Further, AMC's confidence in our digital projection system is a terrific endorsement. We look forward to rolling out our ground-breaking new technology and delivering the premium experience that moviegoers have come to expect from the IMAX® brand."

In October of this year, IMAX announced that it had moved up the launch date of its digital projection system to mid-2008 from its previously announced anticipated timeframe of the end of 2008 to mid-2009. The highly anticipated IMAX digital projection system will further enhance The IMAX Experience and help to drive profitability for studios, exhibitors and IMAX theatres by virtually eliminating the need for film prints, increasing program flexibility and ultimately increasing the number of movies shown on IMAX screens.

IMAX has already secured important parts of its film slate for 2008, 2009 and 2010 through agreements with major Hollywood studios including: The Spiderwick Chronicles (February 2008), Shine A Light (April 2008), Kung Fu Panda (June 2008), The Dark Knight (July 2008), Deep Sea-quel 3D (working title, February 2009), Monsters vs. Aliens 3D (March 2009), How to Train Your Dragon 3D (November 2009), Hubble 3D (working title, February 2010) and Shrek Goes Forth 3D (May 2010).

Added Messrs. Gelfond and Wechsler, "An agreement of this magnitude significantly jumpstarts our joint venture initiative, which we expect will generate increased recurring revenues for IMAX going forward. AMC's decision to enter into this agreement will accelerate the growth of our theatre network in North America and should help power the digital transition underway at our company, which we believe will help drive our operating and financial performance for years to come."

About AMC Entertainment Inc.

Headquartered in Kansas City, Mo., AMC Entertainment Inc. is one of the world's largest and most innovative theatrical exhibition companies. With a history of industry leadership dating back to 1920, the company today serves more than 230 million guests annually through interests in 358 theatres with 5,128 screens in six countries. Visit www.amctheatres.com for more information.

EDGELINE HOLDINGS (OTCBB: ELHI)
"Up 34.88% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ELHI.php

Headquartered in Houston, Texas, Edgeline Holdings, Inc. is a publicly traded holding company that specializes in the area of discovering and acquiring leading-edge niche technologies. These technologies will be incubated and nurtured into market ready applications. Edgeline's current and prospective portfolio consists of early stage companies that require management expertise to further develop the technology to ultimately maximize the value of such technologies by bringing them to market through licensing arrangements and partnerships.

ELHI News:

December 5 - Edgeline Holdings Signs Exclusive Option Agreement with The University of Texas M. D. Anderson Cancer Center

Edgeline Holdings, Inc. (OTCBB:ELHI) announced today that it has signed an Option agreement with The University of Texas M. D. Anderson Cancer Center that provides Edgeline Holdings the exclusive right to negotiate a license to five technologies relating to the treatment of various cancers over a nine month period. During this period the company has the right to evaluate the patents rights, potential products and markets, and to negotiate a license for the use of these patents.

“This agreement gives us the necessary time to allow our subsidiary, Intertech Bio, to properly evaluate the potential of these technologies,” stated Leonard Ivins, Chief Executive Officer of Edgeline Holdings. “M. D. Anderson has been a leader in developing new cancer therapies and we are excited about the opportunity to work with such a great institution.”

MM2 GROUP, INC (OTCBB: MMGP)
"Up 13.33% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MMGP.php

MM2 Group, Inc., through its subsidiary, Genotec Nutritionals, Inc., engages in the formulation, marketing, and distribution of nutritional supplements and vitamins in the United States. It sells various products, including fish oil, grape powder, resveratrol, lutein, and psyllium powder, as well as various custom formulations, such as formulations for diet, cardiac support, eye support, immunity support, and aging support. The company also sells custom formulations for pet care, including a shedding formula, a coat formula, dog and cat joint formulas, and pet multi-vitamins for dogs and cats. MM2 Group is based in Livingston, New Jersey.

MMGP News:

December 7 - MM2 Group Establishes New Venture for Sofgel Manufacture in China

MM2 Group, Inc. (OTCBB: MMGP) announced that its wholly-owned subsidiary, Genotec Nutritionals, Inc., a New York based nutraceutical company which generates its sales from the distribution of its branded products and through custom formulations for several large strategic partners, has entered into a strategic venture to manufacture sofgel capsules in Zhongsan City, China.

The current capacity of the state of the art plant is 1.5 billion capsules per year. The plant was designed and built according to the latest cGMP requirements, in full compliance with both U.S. and China standards. The plant is capable of expanding capacity to 5 billion sofgel capsules per year.

Genotec's partner in this new venture is Anshi Pharmaceutical (Zhongsan) Inc. of China.

Anshi Pharmaceutical is a well regarded company in China. Its Executive Chairman, Mr. Xiaoxian Xu, is a famous entrepreneur in China who previously founded Livzon Pharmaceutical Group, a well known publicly-traded pharmaceutical company in China. Anshi is well positioned to provide research and development, manufacturing, and export services to the pharmaceutical and nutraceutical industries in the United States.

George Kontonotas, President of Genotec, stated, "We are very excited about this venture. The plant is a China SFDA certified facility that complies with cGMP manufacturing standards. These high standards, which allow the plant to currently manufacture pharmaceuticals, make this among the highest quality plants which can be found manufacturing products in the nutritional supplement marketplace."

Mark Meller, CEO of MM2 Group, commented, "We have already met with some of the largest users of sofgels in the nutritional supplement market. Our current focus is to supply large quantities of Vitamin E capsules to several users. We are now negotiating supply agreements with various companies, and hope to be in a position to make several exciting announcements in the near future regarding sales activity from this new venture."

Meller continued, "We are excited about our business prospects. We recently announced net income of $951,855 for our fiscal first quarter, up from a loss of $1,379,761 in the same period last year. We announced last week that we secured a large $1.1 million order for our omega-3 fish oil sofgels. We also recently announced a listing on the Frankfurt Stock Exchange, which we expect will give us greater visibility in Europe and will provide us with an opportunity to broaden our shareholder base to Europe. We anticipate that we will be in a position to announce more exciting business developments in the near future."

CATALYST PHARMACEUTICALS PARTNERS (NASD: CPRX)
"Up 14.13% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CPRX.php

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. CPP-109 recently was selected as one of the five most promising drugs entering Phase II trials in the July-September 2007 issue of The Ones To Watch, published by Thomson Scientific, a Thomson Corporation publication. For more information about the Company, go to www.catalystpharma.com.

CPRX News:

December 7 - Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction

• Study Demonstrates Statistically Significant Efficacy vs. Placebo
• Trial Conducted Under Direction of New York University School of Medicine

Catalyst Pharmaceutical Partners, Inc. (NASD: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, announced positive initial top-line results from an investigator-initiated Phase II double-blind, placebo-controlled trial, which demonstrates that vigabatrin is effective for the treatment of cocaine addiction. Catalyst's lead compound, CPP-109, is bioequivalent to vigabatrin.

This 103 subject trial is the first randomized, double-blind, placebo- controlled clinical trial studying vigabatrin's effectiveness in treating cocaine addiction. These data show that a statistically significantly greater number of subjects treated with vigabatrin were able to abstain from cocaine usage during the last three weeks of the dosing period compared to those receiving placebo. Achievement of abstinence for an extended period during treatment is the critical first step for cocaine addicted patients to potentially achieve abstinence for much longer time periods. The data confirm the positive results seen in two previous open-label trials conducted in 2003 and 2004 by the same investigators.

Commenting on the trial results, Patrick J. McEnany, Catalyst's Chairman and Chief Executive Officer, stated, "This trial represents a key development in the field of cocaine addiction research. CPP-109, our product candidate based on vigabatrin, could have a significant impact on how patients struggling with cocaine addiction will be treated in the future. We believe that the success of the trial provides scientific proof of concept. We are highly encouraged by the top-line results and look forward to publication of the results in a peer-reviewed journal. Catalyst will also evaluate the methodology and results for their potential applicability to our ongoing U.S. Phase II trial evaluating CPP-109 for the treatment of cocaine addiction and to our planned U.S. Phase II trial evaluating CPP-109 for the treatment of methamphetamine addiction."

About The Trial

This trial is the third in a series of human trials conducted in Mexico, which successfully tested the safety and efficacy of vigabatrin to treat cocaine and/or methamphetamine addiction. These trials followed more than 15 years of animal studies conducted by Dr. Stephen Dewey at Brookhaven National Laboratory. All three human trials were conducted under the direction of Dr. Jonathan Brodie, the Marvin Stern Professor of Psychiatry at the New York University (NYU) School of Medicine and Dr. Emilia Figueroa, Director of the Clinica Integral de Tratamiento Contra las Adicciones, S.A. de C.V. The first two trials were small open-label studies. The trial's protocol was approved by NYU's Institutional Review Board in May 2006 and the Federal Commission for Sanitary Risks Protection (Mexico) in September 2006 and is registered at www.clinicaltrials.gov with the identifier NCT00527683. Catalyst provided financial support through an unrestricted gift to NYU.

One hundred and three community-based, non-hospitalized cocaine addicted individuals participated in this investigator-initiated, randomized, double- blind, placebo-controlled trial conducted at a single site in Mexico City. All subjects had ready access to cocaine and were self-motivated to stop their use. The trial was designed to show whether vigabatrin treatment could significantly increase abstinence compared to placebo. Subjects were randomly assigned to either a placebo or vigabatrin and were treated for a period of nine weeks. Of the 103 participants in the trial, 50 were treated with vigabatrin and 53 received placebo. Twice-weekly urine screening tests were obtained from each subject in order to objectively evaluate each subjects' cocaine use. All subjects were also offered one group counseling session per week.

The primary outcome measure of the trial was negative urine tests for cocaine for the last three weeks of the nine-week trial.

A total of 18 subjects fulfilled the criteria for the primary outcome measure. Of these, 14 (28%) were treated with vigabatrin versus four (7.6%) who were treated with placebo. A logistic regression utilizing years of cocaine use and average amount per day at baseline yielded statistically significant treatment differences. The p-value was 0.009.

There were no serious adverse events reported in this trial.

"These positive results demonstrate that there is hope for the millions of individuals who suffer from the life threatening consequences of this terrible illness," said Dr. Brodie. "It also demonstrates how a dedicated team of basic scientists and clinicians who persevere in a mission can produce important medical advances by taking an idea from the bench to the community."

SOUTHWALL TECHNOLOGIES (OTCBB: SWTX)
"Up 18.64% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SWTX.php

Southwall Technologies, Inc. develops, manufactures, and markets thin film coatings on flexible substrates for the automotive glass, electronic display, architectural glass, and window film markets. It develops various products that control sunlight in automotive glass, reduce light reflection, reduce electromagnetic radiation and improve image quality in electronic display products, and conserve energy via the application of architectural and after-market window film products. The company's products consist of transparent solar-control films for automotive glass; anti-reflective films for computer screens, including flat panel displays, plasma displays, and reflective films for back-lighting in liquid crystal displays; transparent conductive films for use in touch screen and plasma panel displays; energy control films for architectural glass; and various other coatings. It sells its products to original equipment manufacturers in North America, Europe, the Middle East, and Asia through direct sales force and sales representatives. The company was incorporated in 1979 and is headquartered in Palo Alto, California.

SWTX News:

December 7 - Southwall's Heat Mirror Insulating Glass Achieves Insulation Value of R-20/U-0.05 Equal to the Insulation of a Solid Wall

Southwall Technologies, Inc. (OTCBB: SWTX), the worldwide innovator of high performance, energy-saving films and glass products, announced that the ability of Heat Mirror® insulating glass to insulate against heat loss at a record breaking R-20/U-0.05 insulation value.

R-20 Heat Mirror insulating glass consists of three heat reflective coated films mounted inside an insulating glass unit between two pieces of low-e coated glass. This super insulating glass construction creates four heat-impeding gas-filled cavities and achieves R-20 performance when used in conjunction with a thermally insulated fiberglass frame. Heat Mirror R-20 is a product of Alpen Energy Systems, a leading Southwall customer licensed to fabricate Heat Mirror insulating glass.

“This astounding achievement in energy efficiency is a tribute to the collaborative team effort of Southwall and its window and insulating glass customers who jointly push the envelope in enhancing the performance and value of Heat Mirror technology,” said John Meade, Southwall’s Director of Business Development

Superior to any low-e glass currently available, Heat Mirror is a technologically advanced low emissivity and solar reflective film that can be mounted inside an insulating glass unit in a variety of configurations (one, two or three coated films, uncoated or low-e coated glass) to provide energy conservation performance ranging from R-6 to R-20 to meet the unique requirements of commercial and residential new construction and renovation projects.

Heat Mirror is the technological alternative to coated glass that extends performance well beyond that of generic low-e glass available today. Heat Mirror insulating glass, as well as other innovative glass technologies currently under development, is driving the US Department of Energy to revise the glass performance standards of its Energy Star program that rates the energy efficiency of appliances and building components.

Scheduled to debut as early as 2009, revised Energy Star glass performance standards will make clear that generic low-e glass, with a maximum insulating performance level of R-4, no longer represents a level of energy efficiency required to “transform the market”, a key charter of the agency’s ratings and standards program. Among Energy Star’s objectives is increased market penetration of windows achieving insulating performance of R-10 by 2010, an objective readily achieved by Heat Mirror technology today.

Why is increasing the energy efficiency of glass important? According to Chris Mathis, a founding member of the National Fenestration Rating Council (NFRC), which sets standards for window energy efficiency, 64 percent of the 110 million existing homes in the US have single-pane windows. This contributes 25%-35% of the total energy wasted in buildings and 10% of the total carbon emissions in the US annually.

Southwall Technologies, Inc. introduced the world’s first low-e coated glass product in 1981, a pioneering technology recognized in 2000 by Popular Science magazine as one of the "Top 100 Inventions of the Millennium.” Southwall’s Heat Mirror insulating glass units are available from over 50 window and insulating glass manufacturers worldwide.

MAJESCO ENTERTAINMENT COMPANY (NASD: COOL)
"Up 23.34% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/COOL.php

Headquartered in Edison, NJ, with an international office based in Bristol, UK, Majesco Entertainment Company is an innovative provider of video games for the mass market, with a focus on publishing video games for leading portable systems and the Wii™ console. Product highlights include Nancy Drew™, Cooking Mama 2: Dinner with Friends and Zoo Hospital™ for the Nintendo DS™ and Cooking Mama: Cook Off for the Wii™ console. More information about Majesco can be found online at www.majescoentertainment.com.

COOL News:

December 6 - Majesco Entertainment Names Jesse Sutton Chief Executive Officer

Majesco Entertainment Company (NASD: COOL), an innovative provider of video games for the mass market, appointed Jesse Sutton as its chief executive officer and Allan Grafman as its non-executive chairman of the board.

“As CEO, I will continue to guide Majesco into its next phase of growth by exploring new avenues in the digital entertainment market,” said Jesse. “Most recently, we launched Majesco Studios, which enables us to leverage our technical and design expertise to specifically focus on products and titles targeting the casual gamer. We're excited about the opportunities that will result from this initiative and believe this move furthers our ability to build the same or better product as we do externally with similar or reduced costs. In addition, we are fortunate to announce that Allan Grafman has assumed the role of non-executive chairman of the board. His extensive knowledge of mass market entertainment franchises and the growing interactive media space will help guide the execution of the company’s strategic goals.”

“The board wants to thank Jesse for his strategic leadership and direction over the past 16 months,” said Grafman. “In addition to driving the mass market strategy, Jesse has led expense reductions, financings and multiple new title releases. We are confident in his ability to aggressively build our business as he focuses on expanding the company’s distribution channels and creating partnerships to increase sales.”

Sutton, 38, has served as Majesco’s interim CEO and a member of the board of directors since August 2006 and as president from 1996 to 2006. He has been involved in overseeing all aspects of the company's operations and has been a key architect of the company's mass market strategy.

Grafman, 54, has served as a member of Majesco’s board of directors since April 2007. He is currently the President of All Media Ventures and has been an operating partner of Mercury Capital Partners since 2005. Previously, Grafman served as President of Archie Comics Entertainment and Executive Vice President, Chief Financial Officer of Hallmark Entertainment. From 1983 to 1996, at Tribune Entertainment he served as Vice President and at parent Tribune Company as Managing Director.

CARDIOVASCULAR BIOTHERAPEUTICS (OTCBB: CVBT)
"Up 23.61% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CVBT.php

CardioVascular BioTherapeutics, Inc., a development stage biopharmaceutical company, focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company uses an active pharmaceutical ingredient, the 141 amino acid form of fibroblast growth factor-1, in its drug candidates, which facilitates the growth of new blood vessels in the heart, and other tissues and organs with an impaired vascular system. Its products under development include CVBT-141A, a Phase I clinical trial completed product for use in the treatment of severe coronary heart disease; and CVBT-141B, which is in Phase I clinical trials for the treatment of diabetic, bedridden, and elderly patients suffering from wounds, open sores, and diabetic ulcers. The company also develops CVBT-141C, which has approval for Phase I clinical trials for the treatment of peripheral artery disease. In addition, CardioVascular BioTherapeutics' product portfolio includes CVBT-141D, which is under proof of concept clinical trials stage for the treatment of disc ischemia. Further, it develops CVBT-141E for the treatment of lumbar ischemia and CVBT-141H for the treatment of severe coronary heart disease?injection catheter delivery, which are under pre-clinical research and development stages. The company was founded in 1998 as CardioVascular Genetic Engineering, Inc. and changed its name to CardioVascular BioTherapeutics, Inc. in 2004. CardioVascular BioTherapeutics is headquartered in Las Vegas, Nevada.

CVBT News:

December 5 - Dutton Associates Announces Investment Opinion: CardioVascular BioTherapeutics Maintained at Speculative Buy Rating by Dutton Associates

Dutton Associates continues its coverage of CardioVascular BioTherapeutics (OTCBB: CVBT) maintaining a Speculative Buy rating and a $1.20 target price. The report by Dutton senior analyst Richard West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Knobias, Reuters, and other leading financial portals.

There have been several events announced since our research report of April 5, 2007, which impact the current and future investment status, centering on CardioVascular BioTherapeutics’ (CardioVascular) progress of its drug candidates through the U.S. Food and Drug Administration (FDA) clinical trial process. In a November 28, 2007 Research Note, we reinstated our rating of Speculative Buy and assigned a 12-month price target of $1.20 per share for Cardio. Recently, CardioVascular announced the completion of its Phase I wound healing FDA clinical trial evaluating the safety and tolerability of its protein-based drug candidate CVBT-141B for dermal wound healing, formulated with human fibroblast growth factor -1 (FGF-1). CardioVascular is making positive progress with its ongoing FDA clinical trials for: severe coronary heart disease - surgical delivery and catheter, wound healing, and peripheral artery disease. In a recent question and answer session on a conference call, Cardio discussed the status of the $15.0 million PIPE that is currently on hold and reaffirmed that Cardio would not sell stock below $1.00 per share. Cardio also indicated that management and members of its board of directors are loaning the Company capital (at 6% interest) to allow the company to weather the current liquidity situation. Finally, they noted that the holder of a convertible note had completed its selling of the converted common stock that had been pressuring the stock down this past year.

NORTH-WEST OIL GROUP (OTC: NWOL)
"Up 33.33% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/NWOL.php

Formerly Nord Oil International, North-West Oil Group Inc. is a Russian public oil-producing and oil-distributing company. NWOG is a young, dynamically growing company that offers its services on the oil markets of Moscow, St. Petersburg and other industrial centers of Russia’s European region. The company’s activity lies in the sphere of oil and gas distribution, production and distribution of oil products and petrochemicals, construction of oil refineries.

NWOL News:

December 7 - President of NWOG Inc. Answers Shareholders' Questions

North-West Oil Group Inc. (OTC: NWOL) announced Mr. Malyshev's answers to the questions of shareholders.

Q: Company's assets?
A: The Company has assets in Saratov region: Shalinsky license field; Goryuchinskoye, Stepnovskoye, Severo-Vasnetsovskoye and Kalininskoye fields

Q: Reserves?
A: Current reserves (C1) total around 8 million tons, with four fields in Saratov region (three millions tons). Shalinsky field (around five million tons).

Q: How many actual (not contracted) employees does North West Oil Group Inc. have as of today?
A: 170

Q: Next audit?
A: Audit of the company will be completed in the nearest time. The shareholders will be informed by a relevant news release.

Q: Shares buy-back program?
A: The Company is proceeding with the buy-back, but in smaller volumes than was originally declared.

Q: Current production?
A: 120,000 tons

Q: Profit?
A: Summarizing the results of nine months, net profit amounted to $ 4,372,700. Anticipated profit for 12 months will amount to $ 6.3 million, which is 13.24% higher than in the analogical period last year.

Q: What should be the actual price of the share based on the latest balance?
A: $9.20.

Q: Plans of uplisting / alternative stock exchanges?
A: As soon as the audit is done, the Company will proceed with entering alternative stock exchanges in different countries, including uplisting in the USA.

Q: Status of OAO NK "SaratovNefteGeoFizika" acquisition?
A: The purchase price is $60 million. Negotiations with an English bank were held and a relevant financing structure was elaborated. In accordance with it the bank is prepared to provide $50 million. $10 million the company shall issue in stock on account of prospective increase in share price. So far the reaction of the seller has not been received.

Q: Status of Danziger Vodka acquisition?
A: The Company requested the audited report on Danziger. So far the latter has not been provided on the part of Danziger.

Q: Status of oil terminal in Latvia?
A: Valuation is not completed yet.

Q: Status of refinery in Jordan?
A: The Company applied for participating in the tender. The latter has yet not been appointed.

Q: Status of drilling?
A: Presently two potentially commercial wells are being drilled in Saratov region. It is planned to finish drilling by the end of the year.

"The investment project on carrying out of prospecting works and extraction of hydrocarbonic raw material in Privolzhski federal region." The date of the project preparation was April 2006.

The project is in work in accordance with the approved program. Investments continue to be made.

Q: Assuming the company is awarded the contract for building a refinery in Syria. How do you expect to finance the cost of construction, which has been quoted at over one billion dollars?
A: For now we have already held negotiations with the banks that are interested in investing in this project.

Q: Compensation of shareholders' losses?
A: The details of the compensation program will be further disclosed in news releases.

Q: Reasons for doing the reverse split?
A: The reverse split was aimed at decreasing the amount of shares held by speculators.

Q: Reasons for decrease in share price?
A: Speculation. The management of the company urges honest shareholders not to take their lead from the speculators. We can put an end to speculation only if honest shareholders support the company.

Q: Do you consider buying other companies with shares or loans?
A: Yes.

Q: Is long-term strategy still to buy smaller Russian companies?
A: Yes.

Q: Can you give us an unaudited report of profits for the first three quarters of 2007?
A: No, because speculators can abuse this information.

Q: Are you also taking shares away from the enemies of NWOL through a lawsuit?
A: The company plans to start this after the audit is completed.

Q: Why does the management think adding shares will compensate those of the shareholders who have stayed with the Company from before the merger till present when those added shares will simply decrease the value of all outstanding shares proportionately?
A: Decrease in share price resulting from the issuance of additional shares to cover the losses of the shareholders at the time of the merger can happen only at the initial stage. The audit, the results of which will be received in the nearest time, will contribute to the affirmation of the real value of the company and, consequently, will contribute to the increase in share price. Thus, the compensated shareholders will be able to substantially cover their losses by way of selling the shares at a higher price.

Q: What objectives does the company set with regard to production and drilling in 2008?
A: In 2008 it is planned to increase production by 60 000 tons. This objective will be reached by drilling 5 additional wells.

Q: Where does the company see itself in five years?
A: In five years the management sees NWOG Inc. as a steadily developing company, competing in the Russian and in the world markets, listed in the biggest stock exchanges of the world, acting as operator of considerable projects in the oil sector, expanding its oil assets, proceeding with constant work towards increasing the share price.